Results 31 to 40 of about 5,420 (200)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV

BMC Infectious Diseases, 2023
HIV post- exposure prophylaxis (PEP) is a prevention tool for individuals with a recent potential exposure to HIV. Doravirine has been available since 2019 in combination with tenofovir disoproxil fumarate and lamivudine and has not been evaluated as a ...
Inès Devred, Kick Kayembe, N. Valin, H. Rougier, Bruce Wuembulua Shinga, S. Lambert-Niclot, Thibault Chiarabini, M. Meyohas, K. Lacombe   +8 more
semanticscholar   +1 more source

Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China

Journal of Acquired Immune Deficiency Syndromes, 2022
Background: We aimed to examine the evolution of blood lipids and compare the risk of dyslipidemia between antiretroviral-naive people living with HIV who received tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and efavirenz (EFV) (TDF + 3TC ...
Liqin Sun, Yun He, Liu-mei Xu, Fang Zhao, Yang Zhou, Lukun Zhang, Q. Peng, Haitao Zhang, Qiuyue Zhang, Tingzhi Cao, Ying Song, Siyuan Wang, M. Rao, Xin Jia, Xiaoning Liu, Jing Zhou, Bin Ju, Hui Wang, Jiaye Liu   +18 more
semanticscholar   +1 more source

Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques

EBioMedicine, 2022
Summary Background Vaginal products for HIV prevention that can be used on-demand before or after sex may be a preferable option for women with low frequency or unplanned sexual activity or who prefer not to use daily or long-acting pre-exposure ...
C. Dobard, M. Peet, K. Nishiura, A. Holder, Chuong Dinh, J. Mitchell, G. Khalil, Yi Pan, O. Singh, Timothy J. McCormick, V. Agrahari, Pardeep K. Gupta, S. Jonnalagadda, W. Heneine, M. Clark, J. García-Lerma, G. Doncel   +16 more
semanticscholar   +1 more source

Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy.

Journal of Global Antimicrobial Resistance, 2022
PURPOSE We aimed to investigate the incidence of low-level viremia (LLV) and its impact on virologic failure (VF) in people living with HIV (PLWH) on stable antiretroviral therapy (ART) who switched to co-formulated elvitegravir, cobicistat ...
Jen-Yu Hsu, Hsin-Yun Sun, Tan-Wen Hsieh, Sui‐Yuan Chang, Y. Chuang, Yu-Shang Huang, Ching-Yu Hsiao, Yi-Ching Su, Wen-Chun Liu, Shu-Fang Chang, C. Hung   +10 more
semanticscholar   +1 more source

HIV/HCV-coinfection: which role can new antiretrovirals such as integrase inhibitors play?

European Journal of Medical Research, 2009
End-stage liver disease has become one of the most frequent causes of death in HIV/HCV-coinfected patients. The role of new antiretrovirals in the progression of liver fibrosis has yet to be defined.
Vogel Martin, Nelson Mark
doaj   +1 more source

META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports

Drugs in Context, 2023
Background: Metabolic effects of integrase strand transfer inhibitors (INSTIs) have been reported. The FDA Adverse Event Reporting System (FAERS) is a publicly available database that captures spontaneously reported adverse events.
Milena M Murray, Lara Fakhouri, Spencer E Harpe   +2 more
doaj   +1 more source

Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques

EBioMedicine, 2022
Summary Background Topical on-demand forms for HIV pre-exposure prophylaxis (PrEP) may be a desirable alternative for people that prefer not to use daily PrEP. CONRAD has developed inserts containing tenofovir alafenamide (TAF) and elvitegravir (EVG) for
N. Makarova, Tyana Singletary, M. Peet, James Mitchell, A. Holder, Chuong Dinh, V. Agrahari, Maria C. B. Mendoza, Yi Pan, W. Heneine, M. Clark, J. García-Lerma, James M. Smith, G. Doncel   +13 more
semanticscholar   +1 more source

Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials

HIV Research & Clinical Practice, 2019
Background: The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naive and ART-experienced Asian ...
Yeon-Sook Kim, Shinichi Oka, Ploenchan Chetchotisakd, Amanda Clarke, Khuanchai Supparatpinyo, Anchalee Avihingsanon, Winai Ratanasuwan, Sasisopin Kiertiburanakul, Kiat Ruxrungtham, SangYoun Yang, Susan Guo, YaPei Liu, Moupali Das, Do Tran, Damian McColl, Roberto Corales, Chris Nguyen, David Piontkowsky   +17 more
doaj   +1 more source

Use of Tenofovir Alafenamide/Emtricitabine/Elvitegravir-Cobicistat in HIV-Naive Patients with Advanced Disease: GENIS Study

Journal of Clinical Medicine, 2022
Objective: The primary endpoint of the study was to determine the proportion of patients with HIV RNA < 50 copies/mL at 48 weeks. Design: Phase IV, multicentric, open-label, single-arm clinical trial of participants recruited in 2018–2019 to evaluate the
Javier Perez Stachowski, David Rial Crestelo, A. Moreno Zamora, N. Cabello, P. Ryan, Nuria Espinosa Aguilera, O. Bisbal, Maria Jesus Vivancos Gallego, M. J. Nuñez, J. Troya, Montserrat Domínguez, J. O. Sierra   +11 more
semanticscholar   +1 more source

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

Retrovirology, 2009
Correction to Erik Serrao, Srinivas Odde, Kavya Ramkumar and Nouri Neamati: Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009, 6:25.
Neamati Nouri, Ramkumar Kavya, Odde Srinivas, Serrao Erik   +3 more
doaj   +3 more sources